Proactive Investors CEO Interview – Algernon NeuroScience completes first dosing in Phase 1 clinical study of DMT

image of proactive logo


Algernon Pharmaceuticals CEO Christopher J. Moreau joined Steve Darling from Proactive to share news the Company’s subsidiary Algernon NeuroScience has announced it has completed the first dosing in its Phase 1 clinical study of an intravenous formulation of AP-188 or DMT.

Mr. Moreau explains to Proactive that the safety review committee has approved moving the study forward with an escalated dose after observing no safety or tolerability issues. This study will include up to 60 healthy volunteers enrolled in total, which will include both psychedelic experienced and psychedelic naïve subjects.

Phase 2 acute stroke and rehabilitation studies are expected to commence in stroke patients by the end of 2023.